Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial

Title: Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial
Authors: Pettitt, AR; Jackson, R; Cicconi, S; Polydoros, F; Yap, C; Dodd, J; Bickerstaff, M; Stackpoole, M; Khan, UT; Carruthers, S; Oates, M; Lin, K; Coupland, SE; Menon, G; Kalakonda, N; McCarthy, H; Bloor, A; Schuh, A; Duncombe, A; Dearden, C; Fegan, C; Kennedy, B; Walewska, R; Marshall, S; Fox, CP; Hillmen, P
Publisher Information: Ferrata Storti Foundation
Publication Year: 2020
Collection: White Rose Research Online (Universities of Leeds, Sheffield & York)
Document Type: article in journal/newspaper
File Description: text
Language: English
ISSN: 0390-6078
Relation: https://eprints.whiterose.ac.uk/id/eprint/157281/8/VoR%209646-Article%20Text-71176-2-10-20201118.pdf; Pettitt, AR, Jackson, R, Cicconi, S et al. (23 more authors) (2020) Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial. Haematologica, 105 (12). pp. 2868-2871. ISSN: 0390-6078
Availability: https://eprints.whiterose.ac.uk/id/eprint/157281/
Rights: cc_by_nc_4
Accession Number: edsbas.CD0F4BD5
Database: BASE